title: Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study.
abstract: Valproate is an anticonvulsant, which is also widely used for treating psychiatric disorders. Some clinical trials have demonstrated benefits of valproate augmentation therapy in schizophrenia. Previous meta-analysis showed inconsistent findings because of limited literature at that time. The aim of this study is to update the newer published data by conducting a meta-analysis of clinical efficacy of valproate augmentation therapy in patients with schizophrenia or schizoaffective disorder. Data sources include electronic research through platform of PubMed. Study eligibility criteria, participants, and interventions were as follows: the inclusion criteria included articles discussing comparisons of the treatment effect in schizophrenic patients treated with antipsychotic augmented with valproate and antipsychotics with/without placebo; articles on clinical trials in humans. The exclusion criteria were case reports or series and nonclinical trials. We compared the effect between antipsychotic treatment with valproate augmentation and antipsychotic monotherapy. Data from clinical trials were pooled by random-effects model, and possible confounding variables were examined through meta-regression and subgroup analysis. Data from 11 articles including 889 patients were included into current meta-analysis. We found patients treated with antipsychotics with valproate augmentation showed significantly more improvement in total psychopathology than those treated with antipsychotics only (P = 0.02). Results from open trials, but not from randomized controlled trials (P = 0.20), showed significant improvement (P = 0.01). In addition, the significance only persisted in the studies conducted with a shorter treatment duration (P < 0.001) rather than longer treatment duration (P = 0.23). There is no difference in the dropout rate between valproate augmentation and antipsychotic treatment only (P = 0.14). We could not perform a detailed meta-analysis for every category of antipsychotics, long-term effect, and safety profiles of valproate augmentation therapy in maintenance treatment, safety in pregnant patients, and subtype of schizophrenia. Our meta-analysis highlights the significantly better treatment effect with valproate augmentation therapy in patients with schizophrenia or schizoaffective disorder, and provides important evidence for supporting the practice of valproate augmentation therapy in these patients.
authors.affiliation: From the Department of Psychiatry, Tsyr-Huey Mental Hospital, Kaohsiung Jen-Ai's Home, Taiwan (P-TT, WC, K-YT, H-YW, C-KW); Department of Neurology, E-Da Hospital, Kaohsiung, Taiwan (Y-WC); Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan (P-YL); and Institute for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan (P-YL).
authors.forename: Ping-Tao
authors.initials: PT
authors.lastname: Tseng
authors.forename: Yen-Wen
authors.initials: YW
authors.lastname: Chen
authors.forename: Weilun
authors.initials: W
authors.lastname: Chung
authors.forename: Kun-Yu
authors.initials: KY
authors.lastname: Tu
authors.forename: Hung-Yu
authors.initials: HY
authors.lastname: Wang
authors.forename: Ching-Kuan
authors.initials: CK
authors.lastname: Wu
authors.forename: Pao-Yen
authors.initials: PY
authors.lastname: Lin
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D014635:Valproic Acid
references.citation: Pharmacol Rev. 1990 Sep;42(3):223-86
references.pmid: 2217531
references.citation: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004028
references.pmid: 18646098
references.citation: J Ky Med Assoc. 2002 Jan;100(1):17-22
references.pmid: 11831095
references.citation: Psychiatr Serv. 2004 Mar;55(3):290-4
references.pmid: 15001730
references.citation: Neuropsychopharmacology. 2013 Jan;38(1):138-66
references.pmid: 22948975
references.citation: Biol Psychiatry. 2001 Dec 1;50(11):898-911
references.pmid: 11743944
references.citation: Neuropsychopharmacology. 2003 Nov;28(11):2049; author reply 2052-3
references.pmid: 12968130
references.citation: World J Biol Psychiatry. 2012 Jul;13(5):318-78
references.pmid: 22834451
references.citation: Pharmacopsychiatry. 1998 Jul;31(4):122-5
references.pmid: 9754845
references.citation: Ther Drug Monit. 1999 Jun;21(3):341-5
references.pmid: 10365650
references.citation: Psychiatry Clin Neurosci. 2012 Aug;66(5):463-4
references.pmid: 22834672
references.citation: Int J Geriatr Psychiatry. 2008 Feb;23(2):142-7
references.pmid: 17582828
references.citation: Indian J Psychol Med. 2012 Jan;34(1):76-8
references.pmid: 22661813
references.citation: Am J Psychiatry. 1994 Jan;151(1):123-5
references.pmid: 8267110
references.citation: Neuropsychopharmacology. 2004 Jun;29(6):1217; author reply 1218-20
references.pmid: 15154001
references.citation: Int Clin Psychopharmacol. 2007 Nov;22(6):356-62
references.pmid: 17917554
references.citation: Prog Neurobiol. 1999 May;58(1):31-59
references.pmid: 10321796
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13614-9
references.pmid: 18757738
references.citation: PLoS Med. 2009 Jul 21;6(7):e1000100
references.pmid: 19621070
references.citation: J Clin Psychopharmacol. 2009 Jun;29(3):267-71
references.pmid: 19440081
references.citation: Epigenetics. 2010 Nov-Dec;5(8):730-5
references.pmid: 20716949
references.citation: Schizophr Res. 2004 Sep 1;70(1):33-7
references.pmid: 15246461
references.citation: J Am Acad Child Adolesc Psychiatry. 2002 Jun;41(6):632
references.pmid: 12049437
references.citation: World J Biol Psychiatry. 2013 Feb;14(1):2-44
references.pmid: 23216388
references.citation: J Clin Psychiatry. 2011 Dec;72(12):1602-10
references.pmid: 21813074
references.citation: Neuropsychopharmacology. 2009 Apr;34(5):1330-8
references.pmid: 19052541
references.citation: Br J Psychiatry. 2005 Oct;187:366-71
references.pmid: 16199797
references.citation: Neuropsychopharmacology. 2003 Jan;28(1):182-92
references.pmid: 12496955
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Expert Rev Neurother. 2009 Jan;9(1):55-71
references.pmid: 19102669
references.citation: Neuroscience. 2015 Sep 10;303:595-603
references.pmid: 26197226
references.citation: Neuropsychopharmacology. 2004 Mar;29(3):636; author reply 637-8
references.pmid: 14973433
references.citation: Trends Pharmacol Sci. 2009 Feb;30(2):55-60
references.pmid: 19110320
references.citation: Curr Med Chem. 2004 Feb;11(3):313-27
references.pmid: 14965234
references.citation: J Clin Psychopharmacol. 1999 Aug;19(4):310-5
references.pmid: 10440457
references.citation: Dialogues Clin Neurosci. 2014 Sep;16(3):419-29
references.pmid: 25364290
references.citation: Curr Med Res Opin. 2007 Jun;23(6):1351-65
references.pmid: 17559734
references.citation: J Clin Psychiatry. 1998 Dec;59(12):689-90
references.pmid: 9921707
references.citation: Nat Rev Neurosci. 2004 Jul;5(7):553-64
references.pmid: 15208697
references.citation: Clin Neuropharmacol. 2011 May-Jun;34(3):131-2
references.pmid: 21586920
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: J Clin Psychopharmacol. 2000 Jun;20(3):357-61
references.pmid: 10831024
references.citation: Hillside J Clin Psychiatry. 1989;11(2):199-207
references.pmid: 2577309
references.citation: J Clin Psychiatry. 2004 Jun;65(6):738-9
references.pmid: 15291647
references.citation: Psychiatr Q. 2006 Spring;77(1):81-95
references.pmid: 16397757
references.citation: Epilepsia. 1995;36 Suppl 2:S2-12
references.pmid: 8784210
references.citation: Schizophr Res. 2005 Nov 15;79(2-3):231-8
references.pmid: 15982856
references.citation: J Clin Psychopharmacol. 2014 Oct;34(5):571-6
references.pmid: 24943390
references.citation: Hum Psychopharmacol. 2007 Oct;22(7):469-76
references.pmid: 17729385
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Pharmacopsychiatry. 2007 Jan;40(1):9-13
references.pmid: 17327954
references.citation: PLoS One. 2014 Mar 24;9(3):e92573
references.pmid: 24664210
references.citation: J Clin Psychiatry. 2009 Jun;70(6):932-3
references.pmid: 19573487
references.citation: Psychopharmacol Bull. 1988;24(1):122-4
references.pmid: 3387516
references.citation: Int Clin Psychopharmacol. 2011 Mar;26(2):88-95
references.pmid: 21030870
references.citation: J Clin Psychopharmacol. 2001 Feb;21(1):21-6
references.pmid: 11199943
references.citation: J Clin Psychiatry. 1998 Aug;59(8):430
references.pmid: 9721824
references.citation: Hum Psychopharmacol. 2011 Oct;26(7):517-25
references.pmid: 22031266
references.citation: Hum Psychopharmacol. 2009 Dec;24(8):628-38
references.pmid: 19946935
references.citation: J Clin Psychopharmacol. 2006 Oct;26(5):467-73
references.pmid: 16974186
references.citation: Mol Psychiatry. 2012 Oct;17(10):1007-16
references.pmid: 21788944
references.citation: J Clin Psychiatry. 2004 Jan;65(1):134
references.pmid: 14974493
references.citation: Psychiatr Q. 1998 Winter;69(4):283-300
references.pmid: 9793108
references.citation: Cancer Res. 2005 May 1;65(9):3815-22
references.pmid: 15867379
references.citation: Expert Opin Drug Metab Toxicol. 2009 May;5(5):539-51
references.pmid: 19409030
references.citation: J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):866-7
references.pmid: 11501681
references.citation: Biol Psychiatry. 2007 Oct 1;62(7):773-83
references.pmid: 17586477